Results 51 to 60 of about 557 (132)

Combination Pharmacotherapies for Obesity—Current Evidence and Future Directions

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Combination pharmacotherapy for obesity can enhance weight loss by targeting complementary neuroendocrine and metabolic pathways. Such benefits are largely additive but limited by tolerability, cost and access. This review outlines practical clinical archetypes and a research agenda for safer, more precise and durable combination strategies across ...
A. B. M. Kamrul‐Hasan, Arnav Kalra, Nitin Kapoor, Deep Dutta, Kunal Mahajan, Robin Maskey, Syed Abbas Raza   +6 more
wiley   +1 more source

Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate‐Data Bayesian Longitudinal Meta‐Analysis

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
After discontinuation of semaglutide or tirzepatide, weight regain averaged 1.04 kg/month. Based on a linear model, half of treatment‐associated weight loss was projected to return by approximately 7.5 months and baseline weight by approximately 15 months, highlighting the need for early monitoring and maintenance planning.
Chia Siang Kow, Kaeshaelya Thiruchelvam, Dinesh Sangarran Ramachandram, Abdullah Faiz Zaihan   +3 more
wiley   +1 more source

Pharmacological Treatment of Obesity: A Review of Current and Future Methods [PDF]

Introduction and objective Obesity poses a significant public health challenge due to its association with an elevated risk of various chronic diseases, including cardiovascular conditions, type 2 diabetes, and overall mortality.
Angelina Lęgas, Weronika Rogala, Bartosz Przybysz, Jakub Kawalec, Joanna Smalira, Karolina Rogowska, Karolina Urbańska, Weronika Rutkowska-Kawalec, Katarzyna Pochodowicz, Julia Zawistowska   +9 more
core   +3 more sources

Perspectivas innovadoras en el tratamiento de la obesidad

Revista de la Sociedad Argentina de Diabetes
El tratamiento de la obesidad atraviesa un cambio paradigmático impulsado por el desarrollo de terapias hormonales estimuladas por nutrientes, por la eficacia en la reducción del peso (15-25%) que se aproxima a la obtenida con la cirugía bariátrica, y ...
María Yuma
doaj   +1 more source

Positioning Incretin‐Based and Next‐Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta‐Analyses

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7768-7778, September 2026.
ABSTRACT Background The obesity pharmacotherapy landscape is evolving rapidly, with several approved incretin‐based therapies and an expanding pipeline of investigational compounds targeting multiple metabolic pathways. Conventional evidence syntheses often struggle to accommodate differences in dose selection, treatment duration and stage of clinical ...
Matteo Monami, Benedetta Ragghianti, Edoardo Mannucci   +2 more
wiley   +1 more source

Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?

IntroductionGlucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have changed the landscape of type 2 diabetes (T2D) management due to their cardio-renal benefits, their glucose-lowering efficacy and weight loss (WL) maintenance. However, the response
Eka Melson (12122895), Dimitris Papamargaritis (7749383), Prathima Gogineni (18839104), Melanie Davies (545715)   +3 more
core   +5 more sources

Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants

Diabetes, Obesity and Metabolism
Abstract Aims The combination of cagrilintide and semaglutide (CagriSema) is being developed for the treatment of obesity and type 2 diabetes. The objective of this thorough QT study was to confirm that cagrilintide does not result in a clinically relevant prolongation in cardiac repolarization
Maria B. N. Gabe, Rainard Fuhr, Angela Sinn, Astrid Eliasen, Kasper K. Berthelsen, Anja B. Kuhlman, Tine A. Bækdal, Ayna B. Nejad   +7 more
openaire   +2 more sources

CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure

CagriSema is a combination of amylin (cagrilintide) and glucagon-like peptide-1 (semaglutide) analogues being developed for weight management. Here, we show that CagriSema blunts metabolic adaptation in rats.
Secher, Anna, Raun, Kirsten, Pedersen, Kent, Kuhre, Rune Ehrenreich, Halling, Jens Frey, Jacobsen, Julie Mie, Snitker, Søren, Reitman, Marc L., le Roux, Carel W., Fels, Johannes Josef, Blom, Ida, Hald, Bjørn, Moreno Martinez, Jaime, Lundh, Sofia   +13 more
core   +1 more source

Advancements in the management of obesity: a review of current evidence and emerging therapies [PDF]

Introduction: Obesity is the modern world’s current epidemic, with substantial health and economic impact. This study aimed to provide a narrative overview of the past, currently available, and future treatment options that offer therapeutic and ...
Abdalla Ahmed, Mohammed Altigani, Ssemmondo, Emmanuel, Sathyapalan, Thozhukat, Mark-Wagstaff, Charlotte   +3 more
core   +1 more source

Recent advances in peptide-based therapies for obesity and type 2 diabetes [PDF]

Options for the treatment of type 2 diabetes mellitus (T2DM) and obesity have recently been expanded by the results of several large clinical trials with incretin-based peptide therapies.
Flatt, Peter R, Conlon, J Michael, Bailey, Clifford J   +2 more
core   +1 more source